baccaratlivedealer| Shanghai Lai Shi (002252.SZ): SR604, currently undergoing Phase I clinical studies, is a recombinant protein monoclonal antibody product produced using biosynthetic technology

Gelonghui May 14 丨 Shanghai Lai Shi (002252)(002252baccaratlivedealer.SZ) held a performance briefing meeting on May 13, 2024, asking,"Does the company have synthetic biology?", The company replied that it is currently conducting phase I clinical studiesbaccaratlivedealerSR604 is a recombinant protein monoclonal antibody product produced using biosynthetic technology.

Tags:

Prev: scratchmakeymakey| NetDragon's intraday changes quickly rose by 5.22% to HK$12.501
Next: sanwabuttons| Northbound Capital sold Midea Group net 442 million yuan today